Clinical research
From artificial intelligence breakthroughs to at-home genetic testing, here are some ways COVID-19 has changed the biopharma industry and what we may see in the near future.
The single-shot chikungunya vaccine was shown to be safe and effective against mosquito-transmitted chikungunya disease in a published analysis of Phase III results.
Currently, women with breast and ovarian cancers have limited treatment options. Anixa Biosciences, ImmunoGen and IMV are working to change that.
The trial’s primary endpoint was to assess endometrial health, with additional goals of evaluating the safety and tolerability of the drug.
Agenus and Targovax partner on a KRAS cancer vaccine, Elixirgen and Taisho target aging and Tonix and Mass General team up again to fight kidney transplant rejection.
Gilead Sciences posted some good news: a late-stage study of its antibody-drug conjugate Trodelvy shows promise in slowing the progression of the most common forms of breast cancer.
The FDA clinical hold comes after Alpine reported a patient died during the NEON-2 trial.
OptiNose AS announced that its Phase III ReOpen1 clinical trial met both of its co-primary endpoints. It will be used to treat patients diagnosed with chronic sinusitis.
The Phase I study could potentially result in RP-A501 becoming the first gene therapy for monogenic heart failure.
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
PRESS RELEASES